Cytokines and inflammatory mediators as promising markers of polymyositis/dermatomyositis

• Published in: Current opinion in rheumatology Vol. 32; no. 6; p. 534
• Main Authors: Cerezo, Lucie Andrés, Vencovský, Jiří, Šenolt, Ladislav
• Format: Journal Article
• Language: English
• Published: United States 01.11.2020
• Subjects: Biomarkers - blood; Circulating MicroRNA - blood; Cytokines - blood; Dermatomyositis - blood; Dermatomyositis - diagnosis; Humans; Inflammation Mediators - blood; Muscle Weakness - blood; Myositis - blood; Myositis - diagnosis
• ISSN: 1531-6963
• DOI: 10.1097/BOR.0000000000000744

Idiopathic inflammatory myopathies (IIMs), known also as myositis, represent challenging group of heterogeneous muscle disorders characterized by symmetric proximal muscle weakness and evidence of muscle inflammation. The purpose of this review is to provide important updates on cytokines and inflammatory mediators related to myositis. In the past 5 years, multiple studies brought a fresh insight into the pathogenesis of myositis by introducing new factors or further characterizing the role of the well established mediators in myositis. Among the mediators reviewed in this article, special attention was paid to interferons, C-X-C motif chemokine ligand 10, interleukin-18 and the IL23/Th17 axis. Some of the recent work has also focused on the nontraditional cytokines, such as adipokines, myokines, S100 proteins, High Mobility Group Box 1 or B-cell activating factor and on several anti-inflammatory mediators. Moreover, microRNAs and their potential to reflect the disease activity or to regulate the inflammatory processes in myositis have recently been subject of intensive investigation. Some of the above-mentioned mediators have been proposed as promising clinical biomarkers or therapeutic targets for myositis. Several recent studies contributed to a better understanding of the pathogenesis of myositis and highlighted the clinical significance of certain inflammatory mediators. Application of these new findings may help to develop innovative approaches for patients' phenotyping, disease activity monitoring and potentially novel therapies.